Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.

Severe psoriasis treated with a new macrolide : Everolimus / E. Frigerio, M.D. Colombo, C. Franchi, A. Altomare, C. Garutti, G.F. Altomare. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 156:2(2007), pp. 372-374. [10.1111/j.1365-2133.2006.07602.x]

Severe psoriasis treated with a new macrolide : Everolimus

G.F. Altomare
2007

Abstract

Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.
Ciclosporin; Everolimus; Psoriasis
Settore MED/35 - Malattie Cutanee e Veneree
2007
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/43238
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 28
social impact